New study tracks dupilumab for chronic hives in Real-World settings
NCT ID NCT07316114
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This study watches 400 people with chronic spontaneous urticaria (long-lasting hives) who are prescribed dupilumab by their doctor. Researchers collect information from medical records and patient surveys to see how the drug works in real life, its safety, and how it affects quality of life. The study lasts 24 months and does not test a new treatment—just observes what happens during routine care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
1 person
The number who actually took part.
- Started
-
Mar 2026
- Finished
-
Jun 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study aims to enroll approximately 10% to 20% adolescents (that is, participants aged 12 to 17 years) of the total 400 participants. If the adolescent enrollment target is not met toward the end of the period, adult enrollment may be temporarily paused to allow more adolescents to enroll.
- Ages
-
12 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients aged 12 years or older at the time of informed consent/assent. * Physician decision to treat the patient with dupilumab for chronic spontaneous urticaria (CSU) made prior to and independently of the patient's participation in the study. * Patient is able to understand and complete study-related questionnaires. * Patients and/or parent/legally authorized representative provide voluntary informed consent and/or assent to participate in the study before inclusion in the study. Exclusion Criteria: * Patients who have a contraindication to dupilumab according to the approved prescribing information label. * Any condition that the treating physician or virtual Investigator believes may interfere with the patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from completing the schedule of assessments. * Patients currently participating in any interventional clinical trial. * Prior use of dupilumab within 6 months of the baseline assessment. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic spontaneous urticaria are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Virtual Research Coordination Center
Wilmington, North Carolina, 28401-3331, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.